Results 1 to 10 of about 15,848 (126)

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses

Journal of Hematology and Oncology, 2017
Background Myelofibrosis (MF) is associated with a variety of burdensome symptoms and reduced survival compared with age-/sex-matched controls. This analysis evaluated the long-term survival benefit with ruxolitinib, a Janus kinase (JAK)1/JAK2 inhibitor,
Ruben Mesa, Alessandro Maria Vannucchi, Jean-Jacques Kiladjian   +2 more
exaly   +3 more sources

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of Hematology and Oncology, 2017
Background The randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial evaluated the JAK1/JAK2 inhibitor ruxolitinib in patients with intermediate-2/high-risk myelofibrosis.
Vikas Gupta, John F Dipersio, Richard T Silver   +2 more
exaly   +3 more sources

Acute psychosis following initiation of ruxolitinib in post-polycythaemia vera myelofibrosis case report [PDF]

Annals of Hematology
Polycythaemia vera (PV) is a myeloproliferative neoplasm (MPN) which can progress to myelofibrosis (MF), a phenomenon termed post-PV MF. Ruxolitinib is a Janus activated kinase (JAK) inhibitor that targets JAK1/2 mutations and is approved for treatment ...
Louise Jade Potter, Sachin Shetty, M. Mansour Ceesay   +2 more
doaj   +2 more sources

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study [PDF]

Annals of Hematology
Chronic graft-versus-host disease (cGVHD) is a major complication for long-term survivors after hematopoietic cell transplantation (HCT). Bronchiolitis obliterans syndrome (BOS) is the crucial manifestation of lung cGVHD. Ruxolitinib has been approved by
Yuqing Tu, Lingyi Yang, Yaxin Cheng, Yanming Zhang, Yinghao Lu, Shushu Xu, Xiaoli Li, Mimi Xu, Mengqi Xiang, Yi Fan, Yuhua Ru, Yang Xu, Feng Chen, Xiaojin Wu, Yulian Zheng, Fei Li, Yue Han, Xiaowen Tang, Huiying Qiu, Miao Miao, Ye Zhao, Xiaoyu Zhu, Depei Wu, Jia Chen   +23 more
doaj   +2 more sources

Hypertriglyceridemia-Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report [PDF]

Case Reports in Oncological Medicine
Ruxolitinib is a Janus kinase inhibitor that has been associated with lipid abnormalities, including a 15% incidence of hypertriglyceridemia. We describe a case of a 37-year-old man with refractory T-cell lymphoma treated with ruxolitinib for ...
Sarah Medina, Leslie A. Ynalvez, Hyeon-Ju Ryoo Ali, Maria E. Cabanillas, Ihab Hamzeh, Salil Kumar, Nicolas Palaskas, Anita Deswal, Shaden Khalaf   +8 more
doaj   +2 more sources

c-Src binds to the cancer drug Ruxolitinib with an active conformation. [PDF]

PLoS ONE, 2014
The cancer drug Ruxolitinib is a potent janus kinase inhibitor approved for the treatment of the myeloproliferative neoplasms. In addition, Ruxolitinib has weak inhibitory activity against a panel of other kinases, including Src kinase.
Yankun Duan, Lin Chen, Yongheng Chen, Xue-gong Fan   +3 more
doaj   +1 more source

Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2V617F myeloproliferative neoplasms

Blood Cancer Journal, 2023
The Janus kinase 2 (JAK2)-driven myeloproliferative neoplasms (MPNs) are chronic malignancies associated with high-risk complications and suboptimal responses to JAK inhibitors such as ruxolitinib.
Charly Courdy, Loïc Platteeuw, Charlotte Ducau, Isabelle De Araujo, Emeline Boet, Ambrine Sahal, Estelle Saland, Valérie Edmond, Suzanne Tavitian, Sarah Bertoli, Pierre Cougoul, Fanny Granat, Laura Poillet, Caroline Marty, Isabelle Plo, Jean-Emmanuel Sarry, Stéphane Manenti, Véronique Mansat-De Mas, Carine Joffre   +18 more
doaj   +1 more source

Salvage Therapy With Low-Dose Ruxolitinib Leads to a Significant Improvement in Bronchiolitis Obliterans Syndrome in Patients With cGVHD After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers in Pharmacology, 2021
Bronchiolitis obliterans syndrome (BOS) is a life-threatening pulmonary manifestation of chronic graft versus host disease (cGVHD) post-allogeneic hematopoietic stem cell transplantation (HSCT), without clear standard of care.
Yanmin Zhao, Yanmin Zhao, Guifang OuYang, Jimin Shi, Jimin Shi, Yi Luo, Yi Luo, Yamin Tan, Yamin Tan, Jian Yu, Jian Yu, Huarui Fu, Huarui Fu, Xiaoyu Lai, Xiaoyu Lai, Lizhen Liu, Lizhen Liu, He Huang, He Huang   +18 more
doaj   +1 more source

Exploring redox vulnerabilities in JAK2V617F-positive cellular models

Hematology, Transfusion and Cell Therapy, 2021
Background: In Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) models, reactive oxygen species (ROS) are elevated and have been implicated in genomic instability, JAK2/STAT signaling amplification, and disease progression. Although the
Keli Lima, Lucia Rossetti Lopes, João Agostinho Machado-Neto   +2 more
doaj   +1 more source

Diagnosis and Treatment of Myeloproliferative Neoplasms With PCM1-JAK2 Rearrangement: Case Report and Literature Review

Frontiers in Oncology, 2021
Myeloproliferative neoplasm (MPN) with PCM1-JAK2 rearrangement is a rare disease with poor prognosis and lacks uniform treatment guidelines. Several studies confirmed the efficacy of ruxolitinib in hematological malignancies with PCM1-JAK2 fusion, but ...
Yingxin Sun, Yingxin Sun, Yifeng Cai, Jia Chen, Jia Chen, Jiannong Cen, Jiannong Cen, Mingqing Zhu, Mingqing Zhu, Jinlan Pan, Jinlan Pan, Depei Wu, Depei Wu, Aining Sun, Aining Sun, Suning Chen, Suning Chen   +16 more
doaj   +1 more source